Evidence map›Paper›PMID 26550114›Full record

ArticleInternational journal of clinical and experimental medicine2015

Up-regulation of miR-506 inhibits cell growth and disrupt the cell cycle by targeting YAP in breast cancer cells.

Kaiyao Hua, Weiguo Yang, Hongming Song, Jialu Song, Chuankui Wei, Dengfeng Li, Lin Fang

Abstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. [YAP1 knockdown suppresses the proliferation, migration and invasion of human nasopharyngeal carcinoma cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019
    Article
  8. Article
  9. MiRNA-134 suppresses esophageal squamous cell carcinoma progression by targeting FOXM1.International journal of clinical and experimental pathology · 2019
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kaiyao HuaDepartment of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University Shanghai 200072, China.
Weiguo YangJiangwan Hospital of Shanghai Hongkou District Shanghai 200434, China.
Hongming SongDepartment of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University Shanghai 200072, China.
Jialu SongDepartment of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University Shanghai 200072, China.
Chuankui WeiDepartment of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University Shanghai 200072, China.
Dengfeng LiDepartment of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University Shanghai 200072, China.
Lin FangDepartment of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University Shanghai 200072, China.
Shanghai Tenth People's Hospital · CNPeople's Liberation Army 411 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are a small class of non-coding RNAs that are extensively deregulated in various cancers. They can act as either oncogenes or tumor suppressor genes in human cancer. The purpose of this study was to investigate the crucial role of miR-506 in breast cancer and to validate whether miR-506 could regulate proliferation of breast cancer cells by targeting YAP (Yes-associated protein) gene. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to quantify the expression levels of miR-506 in breast cancer and adjacent non-cancerous breast tissues. To characterize the miR-506 function, MTT assays, colony formation assays, cell migration assays, cell invasion assays and cell cycle assays were used. Finally, luciferase reporter assays were performed to validate the regulation of a putative target of miR-506, in corroboration with western blot assays. We found that expression of miR-506 was commonly down-regulated in breast cancer cells and breast cancer specimens when compared with that in non-malignant breast epithelial cells and adjacent normal tissues. Up-regulation of miR-506 inhibited cellular proliferation, migration and invasion as well as disrupt the cell cycle of breast cancer cells. Luciferase assays revealed that miR-506 directly bound to the 3'-untranslated region (3'-UTR) of YAP. Western blot analysis verified that miR-506 regulated the expression of YAP at the protein levels. These findings suggest that miR-506 exerts as a tumor suppressor in breast cancer and up-regulation of miR-506 expression inhibits cellular growth, cell migration and invasion as well as disrupt the cell cycle by targeting YAP. Our study demonstrates that the miR-506/YAP axis may help us better understand the molecular mechanisms of breast cancer progression.

Indexed as

breast cancerMiR-506YAP

Identifiers

PMID26550114
PMCPMC4612799
OpenAlexW2195552087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.